Meet the DHBN Spring 2017 Companies: Quio

Smart device to monitor medication injections at home

Alex Dahmani observed something surprising about emerging treatments for autoimmune disorders. Many new therapies involved injectable medications that patients administered themselves, but there was no good way to monitor home injections.

“I was blown away knowing these expensive drugs were being sent home with little more than a syringe,” Dahmani says.


The observation marked the genesis of QuiO, the company Dahmani founded to develop smart injection devices and connected software that tracks drug delivery.

Like many digital health entrepreneurs, Dahmani started out as a scientist, pursuing a doctorate in microbiology and immunology at Columbia University and working in Columbia’s technology transfer office. He eventually left the program to focus full time on QuiO.

The company has developed two SmartinjectorTM devices. The Si One is compatible with syringe-based medications and is designed for home use. The Si Pen works with cartridge-based medications, such as insulin, and can be used on-the-go.

Both devices use sensors to monitor needle insertion, drug delivery, and needle extraction. They automatically transmit injection data to clinicians or researchers—no syncing or smartphone required.

QuiO’s injection management platform, ConnectedRxTM, lets care teams securely monitor individual patients, while enabling organizations to analyze aggregate data to determine real-world drug performance. The platform can integrate data from other kinds of health devices and can deliver medication reminders and health tips directly to patients.

“Almost half of the pharmaceutical pipeline is injectables,” Dahmani says. Treatments for autoimmune disorders represent the biggest market, but more and more patients are administering injections for multiple sclerosis, high cholesterol, anemia, and other diseases—even cancer—at home.

QuiO has emerged as a startup to watch, most recently winning a spot in the Digital Health Breakthrough Network’s spring 2017 class. The company will use the opportunity to further test its Si One device with real patients and providers.

“With a patient-facing product, you can never do too much patient testing,” Dahmani says. “Studies like these are such an important part of our development process.”